Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
agilon health, inc. Market Cap
From what 19 stock analysts predict, the share price for agilon health, inc. (AGL) might increase by 73.52% in the next year. This is based on a 12-month average estimation for AGL. Price targets go from $1.75 to $11. The majority of stock analysts believe AGL is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
AGL is a stock in Healthcare which has been forecasted to be worth $3.62667 as an average. On the higher end, the forecast price is $11 USD by from and on the lower end AGL is forecasted to be $1.75 by Daniel Grosslight from Citigroup.
These are the latest 20 analyst ratings of AGL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sean Dodge RBC Capital | Outperform | $3 | Reiterates | Nov 19, 2024 |
| Daniel Grosslight Citigroup | Sell | $1.75 | Maintains | Nov 13, 2024 |
| Craig Jones Stifel | Hold | $2 | Maintains | Nov 12, 2024 |
| Gary Taylor TD Cowen | Hold | $2 | Maintains | Nov 11, 2024 |
| Constantine Davides JMP Securities | Market Perform | Downgrade | Nov 11, 2024 | |
| Andrew Mok Barclays | Underweight | $2 | Maintains | Nov 11, 2024 |
| Ryan Daniels William Blair | Market Perform | Downgrade | Nov 8, 2024 | |
| Daniel Grosslight Citigroup | Sell | $2.5 | Downgrade | Oct 29, 2024 |
| Elizabeth Anderson Evercore ISI Group | In-Line | $4 | Maintains | Oct 8, 2024 |
| Kevin Fischbeck B of A Securities | Underperform | $3 | Downgrade | Oct 2, 2024 |
| George Hill Deutsche Bank | Hold | $4 | Maintains | Aug 9, 2024 |
| Bill Sutherland Benchmark | Buy | $9 | Reiterates | Aug 8, 2024 |
| Sean Dodge RBC Capital | Outperform | $8 | Reiterates | Aug 7, 2024 |
| Elizabeth Anderson Evercore ISI Group | In-Line | $7 | Maintains | Jul 9, 2024 |
| Michael Halloran Baird | Neutral | $6 | Initiates | May 30, 2024 |
| Jailendra Singh Truist Securities | Hold | $6.5 | Maintains | May 24, 2024 |
| Craig Jones Stifel | Hold | $7 | Maintains | May 1, 2024 |
| Daniel Grosslight Citigroup | Neutral | $6 | Initiates | Apr 22, 2024 |
Truist Securities | Hold | Maintains | Apr 15, 2024 | |
| Andrew Mok Barclays | Underweight | $5 | Initiates | Mar 6, 2024 |
When did it IPO
2021
Staff Count
1,117
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Steven Jackson Sell
Market Cap
$688.1M
In 2023, AGL generated $4.32B in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AGL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - AGL, AFLYY, and BATRK have been assigned a Zacks Rank #5 (Strong Sell) as of November 19, 2024.
Why It Matters - AGL, AFLYY, and BATRK being added to the Zacks Rank #5 (Strong Sell) indicates potential underperformance, signaling investors to reassess their positions in these stocks.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - AOS, AGL, and ABG were added to the Zacks Rank #5 (Strong Sell) List on November 13, 2024, indicating potential concerns for these stocks.
Why It Matters - AOS, AGL, and ABG's addition to the Zacks Rank #5 (Strong Sell) indicates potential declines in stock performance, signaling investors to reassess their positions.
Sun, 10 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Agilon Health, Inc. (NYSE: AGL) held its Q3 2024 earnings call on November 7, 2024, featuring key executives and analysts from major financial institutions.
Why It Matters - Agilon Health's Q3 earnings call provides insights into financial performance and strategic direction, crucial for assessing growth potential and market positioning in healthcare investing.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Agilon Health (NYSE: AGL) reported $150 million in gross savings from its ACOs for 2023, including $37 million for the Medicare Trust Fund, achieving a 13% savings rate.
Why It Matters - Agilon Health's $150 million savings in ACOs signals strong performance and effective cost management, enhancing its financial outlook and potentially boosting investor confidence.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Agilon Health, Inc. (NYSE: AGL) reported growth in membership across 26 partnerships for Q3 2024, emphasizing its full-risk model for senior care.
Why It Matters - Agilon Health's growing membership and focus on high-quality care signal strong demand and potential revenue growth, making it an attractive prospect for investors in the healthcare sector.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Agilon Health (AGL) reported a quarterly loss of $0.29 per share, worse than the expected loss of $0.10, and a decline from a loss of $0.06 per share in the same quarter last year.
Why It Matters - Agilon Health's larger-than-expected quarterly loss raises concerns about its financial health and operational efficiency, potentially impacting stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
